Versant Ventures is an institutional investor (Conventional VCs) founded in 1999 and headquartered in San Francisco, United States. Versant Ventures is an early and late-stage venture capital firm that invests in the US and Europe. It makes the investment in life sciences companies operating in sectors such as Biopharma, Medical Devices, Diagnostics, etc. Some of the notable portfolio companies are Jazz Pharmaceuticals, Blue Rock Therapeutics, AcuFocus, CymaBay Therapeutics, etc. The firm manages over $2.3B assets under management. Assets Under Management (AUM): manages over $2.3B. Notable portfolio companies: Jazz Pharmaceuticals, Blue Rock Therapeutics, AcuFocus, CymaBay Therapeutics.

Stage

seed, Series A, Series B+, growth, late-stage, post-IPO, seed, Series A, Series B+, growth, late-stage, post-IPO

Check size

$1M-$50M

HQ

Basel, Switzerland

Founded

1999

Website

https://www.versantventures.com/

LinkedIn

https://linkedin.com/company/versant-ventures

Twitter

http://twitter.com/versantventures

What they look for

Academic founders or experienced biotech teams; US, Canada, Europe (esp. Switzerland); breakthrough therapeutics for serious diseases; sustainable business models with dual liquidity paths

Preparing to pitch Versant Ventures?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.